Can we predict which kids will respond to migraine drug?

NCT ID NCT07180043

Completed Knowledge-focused Sponsor: Kayseri University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study in 178 children aged 6-16 with migraine compared the drug propranolol to structured behavioral therapy. Researchers looked for clinical and biochemical factors that might predict who responds best to propranolol. The goal is to help personalize migraine prevention in children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: propranolol
What this could lead to: If successful, this could help doctors predict which children with migraine will benefit most from propranolol, leading to more personalized treatment.
What could go wrong: This is an observational study, not a randomized trial, so results may not prove cause and effect. The findings are also specific to children aged 6-16 and may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEADACHE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEADACHE DISORDERS PEDIATRIC MIGRAINE

Contacts and locations

Locations

Kayseri University

Kayseri, Kayseri, 38130, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.